Insights and Experiences in CML Patients Treated with a 2nd Generation TKI

Chair: Prof. Carlo Gambacorti-Passerini, Italy
Insights and Experiences in CML Patients Treated with a 2nd Generation TKI

Chair: Prof. Carlo Gambacorti-Passerini, Italy

07.30 - 08.00 Breakfast

08.00 - 08.05 Welcome and introduction
   Prof. Carlo Gambacorti-Passerini
   Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Milano, Italy

08.05 - 08.30 Synergistic targets in CML - Specific dual inhibition of BCR-ABL and SRC
   Dr. Joseph Boni
   Team Lead Clinical Pharmacology, Pfizer Oncology

08.30 - 09.00 Clinical efficacy of bosutinib in newly diagnosed CML patients and relapsed, refractory CML patients
   Prof. Carlo Gambacorti-Passerini
   Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Milano, Italy

09.00 - 09.30 Safety profile and therapy management in CML patients receiving bosutinib
   Prof. Tim Brümmendorf
   Department of Hematology and Oncology, University Hospital Aachen, Aachen, Germany

09.00 - 09.30 Safety profile and therapy management in CML patients receiving bosutinib
   Prof. Tim Brümmendorf
   Department of Hematology and Oncology, University Hospital Aachen, Aachen, Germany

09.30 - 09.55 Future strategies in CML treatment
   Prof. Giovanni Martinelli
   Institute of Hematology and Medical Oncology, University of Bologna, Bologna Italy

09.55 - 10.00 Conclusion
   Prof. Carlo Gambacorti-Passerini
   Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Milano, Italy

1ONCO1109007 Date of preparation: August 2011